Davis Polk advised Royalty Pharma plc and the selling shareholders on the offering. Royalty Pharma executed its $728 million secondary offering of 17,343,037 of its Class…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
